A new review by U.K. researchers suggests anti-inflammatory drugs similar to those used to treat conditions such as rheumatoid arthritis and psoriasis could, in the future, be used to treat some cases of depression.
University of Cambridge researchers believe the findings further implicate the immune system in mental health disorders. Researchers from the Department of Psychiatry led a team that analyzed data from 20 clinical trials involving the use of anti-cytokine drugs to treat a range of autoimmune inflammatory diseases.
The findings were based on a meta-analysis of seven randomized controlled trials. Moreover, meta-analyses of the other types of clinical trials showed similar results.
Experts explain that when we are exposed to an infection, for example influenza or a stomach bug, our immune system fights back to control and remove the infection. During this process, immune cells flood the blood stream with proteins known as cytokines. This process is known as systemic inflammation.
Even when we are healthy, our bodies carry trace levels of these proteins — known as “inflammatory markers” — which rise exponentially in response to infection. Previous work from the team found that children with high everyday levels of one of these markers are at greater risk of developing depression and psychosis in adulthood.
This link suggests a role for the immune system, particularly chronic low-grade systemic inflammation, in mental illness.
Inflammation can also occur as a result of the immune system mistaking healthy cells for infected cells and attacking the body, leading to autoimmune inflammatory diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
New types of anti-inflammatory drugs called anti-cytokine monoclonal antibodies and cytokine inhibitors have been developed recently, some of which are now routinely used for patients who respond poorly to conventional treatments. Many more are currently undergoing clinical trials to test their efficacy and safety.
The team of researchers carried out a meta-analysis of these clinical trials and found that the drugs led to an improvement in the severity of depressive symptoms independently of improvements in physical illness.
In other words, regardless of whether a drug successfully treated rheumatoid arthritis, for example, it would still help improve a patient’s depressive symptoms. Their results are published in the journal Molecular Psychiatry.
Dr Golam Khandaker, who led the study, says, “It’s becoming increasingly clear to us that inflammation plays a role in depression, at least for some individuals, and now our review suggests that it may be possible to treat these individuals using some anti-inflammatory drugs.
These are not your everyday anti-inflammatory drugs such as ibuprofen, however, but a particular new class of drugs.”
“It’s too early to say whether these anti-cytokine drugs can be used in clinical practice for depression, however,” adds Professor Peter Jones, co-author of the study.
“We will need clinical trials to test how effective they are in patients who do not have the chronic conditions for which the drugs have been developed, such as rheumatoid arthritis or Crohn’s disease. On top of this, some existing drugs can have potentially serious side effects, which would need to be addressed.”
Khandaker and colleagues believe that anti-inflammatory drugs may offer hope for patients for whom current antidepressants are ineffective. Although the trials reviewed by the team involve physical illnesses that trigger inflammation — and hence potentially contribute to depression.
Khandaker’s team has previously found a connection between depression and baseline levels of inflammation in healthy people — that is, when someone does not have an acute infection. This discovery may be explained by a number of factors such as genes and psychological stress.
“About a third of patients who are resistant to antidepressants show evidence of inflammation,” adds Dr Khandaker. “So, anti-inflammatory treatments could be relevant for a large number of people who suffer from depression.
“The current approach of a ‘one-size-fits-all’ medicine to treat depression is problematic. All currently available antidepressants target a particular type of neurotransmitter, but a third of patients do not respond to these drugs.
We are now entering the era of “personalized medicine” where we can tailor treatments to individual patients. This approach is starting to show success in treating cancers, and it’s possible that in future we would use anti-inflammatory drugs in psychiatry for certain patients with depression.”
Source: University of Cambridge